efficacy CRL: Reproxalap dry-eye NDA CRL: efficacy not demonstrated
Price into the decision (T-120)
Daily close, T-120 (10/17/24) through T+5. Run-up high $6.98 on 3/12/25, low $4.21 on 11/25/24 (T-120 to T-1). FDA decision 4/3/25. Historical price action, not a forecast.
Decision facts
FDA decision date2025-04-03
Outcome✗ CRL✓ source-verified
Decision-day move-73.4%
T-120 run-up (low→high)+45.0% ($1.42→$6.98)
CRL reasonefficacy: Reproxalap dry-eye NDA CRL: efficacy not demonstrated